... / ... / ... / Research groups / Experimental Systematic Therapy of Urogenital...

Experimental Systematic Therapy of Urogenital Cancers

The section experimental therapy of Urological Cancers is an integral component of the Department of Medical Oncology and aims to initiate and collaborate in investigator as well as Industry initiated and sponsored clinical trials in Urological cancers. The spectrum includes the entire range of metastatic and non- metastatic and phase 1-3 clinical trials as well as post-marketing (phase 4) health- economics studies. The section leads (RdW is founding Chairman) the Dutch Uro-Oncology Study group (DUOS) and collaborates with other national groups in Europe, such as the Scandic Group and the Spanish Oncology Genitourinary Group (SOGUG), as well as Oncology Trials Insights (OTI) in the United States.

The section is closely linked to the sections Early Clinical Trials, Translational Pharmacology and personalized medicine, and Translational Cancer Genomics and Proteomics, the latter comprising several clinical and translational research programs on Circulating Tumors cells and exosomes, including gene profiling (prostate cancer and bladder cancer). The section also works together with the Center of Personalized Cancer Treatment (CPCT), a collaborative network of Erasmus MC with several academic and supraregional hospitals in the Netherlands. This personalized medicine research is aimed at establishing individualized treatments of patients with solid tumors that are highly effective and show least side effects. Our ambitious vision:“The treatment of an individual with cancer is determined by specific characteristics of that individual patient, the cancer cells, and their micro-environment, and needs to be constantly adjusted according to the changes observed in these characteristics”.

. filmpje second opinion RdeWit


Two key publications
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.Petrylak DP, Vogelzang NJ, Budnik N, Wiechno PJ, Sternberg CN, Doner K, Bellmunt J, Burke JM, de Olza MO, Choudhury A, Gschwend JE, Kopyltsov E, Flechon A, Van As N, Houede N, Barton D, Fandi A, Jungnelius U, Li S, de Wit R, Fizazi K. Lancet Oncol. 2015 Apr;16(4):417-25. PubMed

Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.Saad F, Fizazi K, Jinga V, Efstathiou E, Fong PC, Hart LL, Jones R, McDermott R, Wirth M, Suzuki K, MacLean DB, Wang L, Akaza H, Nelson J, Scher HI, Dreicer R, Webb IJ, de Wit R; ELM-PC 4 investigators.Lancet Oncol. 2015 Mar;16(3):338-48. PubMed

Two recent publications
Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. Smith M, De Bono J, Sternberg C, Le Moulec S, Oudard S, De Giorgi U, Krainer M, Bergman A, Hoelzer W, De Wit R, Bögemann M, Saad F, Cruciani G, Thiery-Vuillemin A, Feyerabend S, Miller K, Houédé N, Hussain S, Lam E, Polikoff J, Stenzl A, Mainwaring P, Ramies D, Hessel C, Weitzman A, Fizazi K. J Clin Oncol. 2016 Sep 1;34(25):3005-13. doi: 10.1200/JCO.2015.65.5597.

Belderbos BPS, Bins S, van Leeuwen RWF, Oomen-de Hoop E, van der Meer N, de Bruijn P, Hamberg P, Overkleeft ENM, van der Deure WM, Lolkema MP, de Wit R, Mathijssen RHJ.Influence of Enzalutamide on Cabazitaxel Pharmacokinetics: a Drug-Drug Interaction Study in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients. Clin Cancer Res. 2018 Feb 1;24(3):541-546. doi: 10.1158/1078-0432.CCR-17-2336.